Showing 1471-1480 of 1857 results for "".
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn to Treat Mild to Moderate Acnehttps://practicaldermatology.com/news/20140204-oculus_innovative_sciences_receives_european_ce_mark_for_use_of_microcyn_to_treat_mild_to_moderate_acne/2459350/
- AMBI Now Part of Valeant Pharmaceuticalshttps://practicaldermatology.com/news/20121221-ambi_now_part_of_valeant_pharmaceuticals/2459653/Johnson & Johnson has sold the AMBI brand to Valeant Pharmaceuticals North America. Valeant is a multinational, pharmaceutical/OTC company based in Bridgewater, NJ.
- GW SMHS Teledermatology Program Receives Renewed Fundinghttps://practicaldermatology.com/news/gw-smhs-teledermatology-program-receives-renewed-funding/2468756/The George Washington University School of Medicine and Health Sciences Department of Dermatology, in collaboration with the Pennsylvania Avenue Baptist Church and the National Psoriasis Foundation (NPF), announced a renewed funding commitment of $350,000 from Johnson & Johnson in support of
- Industry Responds to COVID-19: Janssen Pharmaceutical Companieshttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat-janssen-pharmaceutical-companies/2460694/In response to the COVID-19 pandemic, Janssen Pharmaceutical Companies of Johnson & Johnson, “has been collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existi
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- Gryphon Acquires Roc Skincare from J & Jhttps://practicaldermatology.com/news/gryphon-acquires-roc-skincare-from-j-j/2459930/Gryphon Investors has acquired RoC Skincare from Johnson & Johnson Consumer, Inc. The transaction is Gryphon's second investment in the beauty sector after the firm acquired indie color cosmet
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement